Skip to main content
Premium Trial:

Request an Annual Quote

Bioinn to Distribute Courtagen's NGS Tests in Taiwan

NEW YORK (GenomeWeb) – Courtagen Life Sciences today announced a deal with Bioinn Molecular Diagnosis to provide Courtagen's clinical next-generation sequencing tests for neurological and metabolic disorders in Taiwan.

Courtagen's tests provide information on the genetic causes of disorders including epilepsy, intellectual disability, autism spectrum disorders, and mitochondrial dysfunction.

"The distribution agreement with Bioinn is another important step in the execution of our global strategy to support the increasing demand of our products," Courtagen President Brendan McKernan said in a statement. Financial and other terms of the deal were not disclosed.

Last month, Couragen and Sciencewerke signed an agreement for the international distribution of Courtagen's tests.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.